4KD-29413-26576
1 vaccination
1 coded response
8 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 600 / IL
- Registered
- 2021-01-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-30
Registered in v-safe
-
2021-01-30
Dose 1 — Pfizer-BioNTech
- 2021-01-30
- 2021-01-31
- 2021-02-01
- 2021-02-03
- 2021-02-04
- 2021-02-05
- 2021-07-31
-
2022-02-01
Survey response — 12 months, dose 1MedDRA: Nasopharyngitis — Feeling: Fair · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Mild cold symptomsMedDRA releases: 2024-11 · check-in free text available
-
2022-02-01
Report sent to call center — 12 months, dose 1Be unable to work or attend school · Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-02-04
-
2022-02-15
Call successfulParticipant prefers to complete VAERS report online
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-30 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-01 | Successful 2022-02-15 |
Participant prefers to complete VAERS report online |
Free text
Release 11 — 12 months, dose 1
Symptoms: Mild cold symptoms
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release